Company news

Viridian Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Viridian Therapeutics Secures Flexible Credit Facility for Up to $75 Million From Hercules Capital

April 3, 2022

Viridian Therapeutics Doses First Subject in First-in-Human Clinical Trial Evaluating VRDN-002, a Next Generation IGF-1R Antibody for the Treatment of Thyroid Eye Disease

March 20, 2022

Viridian Therapeutics to Participate in 32nd Annual Oppenheimer Healthcare Conference on March 15

March 13, 2022

Viridian Therapeutics Reports Fourth Quarter And Full Year 2021 Financial Results And Provides Corporate Updates

March 9, 2022

Viridian Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results and Host Investor Conference Call on March 10, 2022

March 2, 2022

Viridian Therapeutics to Participate in the SVB Leerink 2022 Global Healthcare Conference on February 18

February 13, 2022

Viridian Therapeutics Announces FDA Clearance of Investigational New Drug Application to Initiate Clinical Development of VRDN-002, a Next Generation IGF-1R Antibody for the Treatment of Thyroid Eye Disease

January 30, 2022

Viridian Therapeutics Submits Investigational New Drug Application for VRDN-002 to the U.S. Food and Drug Administration

January 3, 2022

Viridian Therapeutics Announces First Subject Dosed in Phase 1/2 Clinical Trial of VRDN-001 for Thyroid Eye Disease (TED)

December 19, 2021

Viridian Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for VRDN-001, an IGF-1R Antibody for the Treatment of Thyroid Eye Disease (TED)

November 14, 2021

Viridian Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Updates

November 3, 2021

Viridian Therapeutics to Present at Upcoming Investor Conferences

November 2, 2021

Viridian Therapeutics Submits Investigational New Drug Application for VRDN-001, an IGF-1R antibody for the treatment of Thyroid Eye Disease, to the U.S. Food and Drug Administration

October 13, 2021

Viridian Therapeutics to Present Preclinical Data on VRDN-001 and VRDN-002 at the 90th Annual Meeting of the American Thyroid Association

September 29, 2021

Viridian Therapeutics Announces Closing of Public Offering of Shares of Common Stock and Preferred Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares

September 22, 2021

Viridian Therapeutics Announces Pricing of Public Offering of Shares of Common Stock and Preferred Stock

September 20, 2021

Viridian Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Updates

August 10, 2021

Viridian Therapeutics to Participate in the Wedbush PacGrow Healthcare Virtual Conference

August 4, 2021

Viridian Therapeutics Appoints Kristian Humer as Chief Financial Officer and Chief Business Officer

July 25, 2021

Viridian Therapeutics Appoints Jennifer Moses, CPA to the Board of Directors and as Chair of the Audit Committee

July 14, 2021

Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

July 13, 2021

Viridian Therapeutics to Present at the Ladenburg Thalmann 2021 Healthcare Conference

July 6, 2021

Viridian Therapeutics to Participate in the JMP Securities Life Sciences Conference

June 9, 2021

Viridian Therapeutics to Participate in Upcoming Investor Conferences

May 13, 2021

Viridian Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Updates

May 5, 2021

Viridian Therapeutics Reports 2020 Financial Results and Provides Corporate Updates

March 24, 2021

Viridian Therapeutics To Host Conference Call Discussing Fourth Quarter And Full Year 2020 Results And Corporate Update

March 8, 2021

Viridian Therapeutics to Present at Three Upcoming Investor Conferences

February 21, 2021

miRagen Therapeutics Announces Company Name Change to Viridian Therapeutics and New Executive Appointments, Including Expansion of Leadership Team

January 18, 2021

miRagen Enters into License Agreement with Xencor for use of Xtend™ Antibody Technology for Investigational Antibodies to Treat Thyroid Eye Disease

December 16, 2020

miRagen Reports Third Quarter 2020 Financial Results and Provides Corporate Updates

November 9, 2020

miRagen Announces Internal Review of Preliminary Topline Data for the Phase 2 SOLAR Clinical Trial of Cobomarsen in Patients with Cutaneous T-Cell Lymphoma (CTCL)

October 4, 2020

miRagen Announces Leadership Transition and Review of Strategic Alternatives

September 13, 2020

miRagen Announces Results of Meeting With FDA Regarding the Design of Pivotal Trial for Cobomarsen in ATLL

August 19, 2020

miRagen Reports Second Quarter 2020 Financial Results and Provides Business Updates

August 4, 2020

miRagen to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference

August 3, 2020

miRagen, Investigators from Goethe University and University Hospital Frankfurt and Servier Publish MRG-110 Phase 1 Pharmacodynamic Biomarker Data in Nucleic Acid Therapeutics

July 27, 2020

miRagen to Report Second Quarter 2020 Financial Results on August 5, 2020

July 21, 2020

miRagen Regains Compliance With Nasdaq Listing Requirements

July 1, 2020

miRagen Announces Encouraging Preclinical Safety and Efficacy Data for its Next-generation miR-29 Replacement Product Candidate Intended for the Treatment of Idiopathic Pulmonary Fibrosis

June 21, 2020

miRagen Strengthens Leadership Team with Appointment of Lee Rauch as Chief Operating Officer

June 17, 2020

miRagen to Host a Key Opinion Leader Call on Idiopathic Pulmonary Fibrosis on Tuesday, June 23rd

June 15, 2020

miRagen to Present at the Jefferies 2020 Virtual Global Healthcare Conference

May 25, 2020

miRagen Reports First Quarter 2020 Financial Results and Provides Corporate Update

May 6, 2020

miRagen Therapeutics to Report First Quarter 2020 Financial Results On May 7, 2020

April 22, 2020

miRagen Reports Fourth Quarter and Full Year 2019 Financial Results

March 10, 2020

miRagen Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results on March 11, 2020

February 19, 2020

miRagen Announces Pricing of $15.0 Million Public Offering of Common Stock and Warrants to Purchase Common Stock

February 6, 2020

miRagen Announces Proposed Public Offering of Common Stock and Warrants to Purchase Common Stock

February 5, 2020

miRagen Therapeutics Announces Positive Data for Cobomarsen in Adult T-Cell Leukemia/lymphoma Patients With Residual Disease

January 29, 2020

← Newer news releases · Older news releases →

Calls

The 5 newest of 7 calls. Every call is listed under its year.

Decks

The 5 newest of 24 decks. Every deck is listed under its year.